Antithrombotic Therapy for Patients Undergoing Cardiac Electrophysiological and Interventional Procedures: JACC State-of-the-Art Review.
Di Biase L, Lakkireddy DJ, Marazzato J, Velasco A, Diaz JC, Navara R, Chrispin J, Rajagopalan B, Natale A, Mohanty S, Zhang X, Della Rocca D, Dalal A, Park K, Wiley J, Batchelor W, Cheung JW, Dangas G, Mehran R, Romero J; ACC Electrophysiology and Interventional Councils.
J Am Coll Cardiol. 2024 Jan 2;83(1):82-108. doi: 10.1016/j.jacc.2023.09.831.
Surgical ablation supplemented by ethanol injection for ventricular tachycardia refractory to percutaneous ablation.
Yang G, Shao Y, Gu W, Ni B, Yang B, Zhang F, Ju W, Chen H, Gu K, Li M, Chen Y, Sun H, Tam TK, Wu Y, Chen M.
J Cardiovasc Electrophysiol. 2021 Sep;32(9):2462-2470. doi: 10.1111/jce.15162. Epub 2021 Jul 21.
Complications and Anticoagulation Strategies for Percutaneous Epicardial Ablation Procedures.
Nakamura T, Davogustto GE, Schaeffer B, Tanigawa S, Muthalaly RG, Kanagasundram A, John RM, Michaud GF, Tedrow UB, Stevenson WG.
Circ Arrhythm Electrophysiol. 2018 Nov;11(11):e006714. doi: 10.1161/CIRCEP.118.006714.
Long-term electrocardiographic findings in patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation.
Haghjoo M.
J Electrocardiol. 2007 Oct;40(4):357.e1-2. doi: 10.1016/j.jelectrocard.2007.04.005.
Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation.
Savelieva I, Camm AJ.
Clin Cardiol. 2014 Jan;37(1):32-47. doi: 10.1002/clc.22204. Epub 2013 Nov 19.
Update on Direct Oral Anticoagulants in Atrial Fibrillation Patients Undergoing Cardiac Interventional Procedures: From Clinical Trials to Real-World Evidence.
Melillo E, Carbone A, Rago A, Papa AA, D' Onofrio A, Nigro G, Golino P, Russo V.
J Cardiovasc Pharmacol. 2020 Mar;75(3):185-199. doi: 10.1097/FJC.0000000000000786.
Percutaneous transluminal septal myocardial ablation in hypertrophic cardiomyopathy.
van der Lee C, Foley DP, Vletter WB, Ten Cate FJ, Kofflard MJ.
Neth Heart J. 2001 May;9(2):75-77.
Cardiac troponin I degradation in serum of patients with hypertrophic obstructive cardiomyopathy undergoing percutaneous septal ablation.
Madsen LH, Lund T, Grieg Z, Nygaard S, Holmvang L, Jurlander B, Grande P, Christensen G, Atar D.
Cardiology. 2009;114(3):167-73. doi: 10.1159/000226596. Epub 2009 Jul 2.
Retrospective Analysis of Risk Factors for Related Complications of Chemical Ablation on Hypertrophic Obstructive Cardiomyopathy.
Li CY, Shi YQ.
Arq Bras Cardiol. 2019 Apr;112(4):432-438. doi: 10.5935/abc.20190060. Epub 2019 Apr 1.
Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines.
Proietti M, Lane DA, Boriani G, Lip GYH.
Can J Cardiol. 2019 May;35(5):619-633. doi: 10.1016/j.cjca.2019.02.009. Epub 2019 Feb 21.
